| Kimberly Brady Sexton, CRNA | |
|
305 Langdon St, Somerset, KY 42503-2750 | |
| (606) 678-3288 | |
| (606) 679-3108 |
| Full Name | Kimberly Brady Sexton |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 14 Years |
| Location | 305 Langdon St, Somerset, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336457639 | NPI | - | NPPES |
| 7100189560 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 276173 (Massachusetts) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 85591 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Lexington | Lexington, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Kentucky Anesthesia P.s.c. | 4880508712 | 49 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Commonwealth Anesthesia, Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437196300 PECOS PAC ID: 5092627521 Enrollment ID: O20031104000115 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Central Kentucky Anesthesia P.s.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518083161 PECOS PAC ID: 4880508712 Enrollment ID: O20031115000040 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Cumberland Anesthesia Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124134192 PECOS PAC ID: 8426957218 Enrollment ID: O20031231000063 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Quality Care Anesthesia Physicians Ltd Co |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366720567 PECOS PAC ID: 7315119609 Enrollment ID: O20111010000525 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Resource Anesthesia Cumberland Valley Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780930743 PECOS PAC ID: 2961652755 Enrollment ID: O20121102000100 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Environ Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831438092 PECOS PAC ID: 3870717754 Enrollment ID: O20140616001501 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Anesthesia Health Consultants |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336528926 PECOS PAC ID: 4688977218 Enrollment ID: O20160114001985 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Entity Name | Providian Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821654666 PECOS PAC ID: 2264765791 Enrollment ID: O20190614000874 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Brady Sexton, CRNA 305 Langdon St, Somerset, KY 42503-2750 Ph: (606) 678-3288 | Kimberly Brady Sexton, CRNA 305 Langdon St, Somerset, KY 42503-2750 Ph: (606) 678-3288 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.
A technology that allows women to have ovarian tissue removed and transplanted back into their ovaries when they want to become pregnant is becoming an "intriguing option" for women who want to delay pregnancy, the Wall Street Journal reports.
A study presented today at the Late Breaking Clinical Trials presentations at the Heart Rhythm Society's Annual Scientific Sessions in New Orleans found that implantable cardiac defibrillators (ICD) benefit patients with recently diagnosed cardiomyopathy, a disease that affects the heart muscle's ability to pump and can lead to heart failure.
Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
A recent study shows that hundreds of genes contribute to cell growth and cell division. For the first time these genes, many of which are potential contributors to cancer, have been mapped in a single systematic study.
› Verified 6 days ago
Justin Timothy Pate, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-678-3288 | |
Benjamin Thomas Kabel, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-678-7441 | |
Daniel G. Patton, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-679-7441 | |
Chelsey Herzig Donohue, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 108 Southridge Dr, Somerset, KY 42503 Phone: 218-349-7479 | |
Lucas Daniel Holcomb, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-679-7441 | |
Eric M Toohey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 305 Langdon St, Somerset, KY 42503 Phone: 606-679-7441 |